KKRC
CLDI icon

Kohlberg Kravis Roberts & Co’s Calidi Biotherapeutics CLDI Stock Holding History

Kohlberg Kravis Roberts & Co’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-294
Closed -$351K – 216
2022
Q2 		$351K Hold
294
– – ﹤0.01% 179
2022
Q1 		$349K Buy
294
+73
+33% +$86.2K ﹤0.01% 191
2021
Q4 		$260K Buy
+221
New +$260K ﹤0.01% 158

Other funds holding CLDI

DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
SFM
Spartan Fund Management Toronto, Ontario, Canada $30M AUM 11.98% 1-Year Est. Return
LSC
Logan Stone Capital Chicago, Illinois $360M AUM 9.71% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return

Kohlberg Kravis Roberts & Co's CLDI Position: Q3 2022 in Review

Kohlberg Kravis Roberts & Co sold out of Calidi Biotherapeutics (CLDI) in Q3 2022, closing a stake of 294 shares — an estimated $351K sold.

Kohlberg Kravis Roberts & Co first reported a position in CLDI in Q4 2021 and held it in 3 quarters. The position peaked at $351K in Q2 2022. 21 funds tracked by Wall St. Rank hold CLDI as of Q3 2022.

  • Kohlberg Kravis Roberts & Co reported no remaining Calidi Biotherapeutics position as of Q3 2022 after selling out during the quarter.
  • Kohlberg Kravis Roberts & Co sold 294 Calidi Biotherapeutics shares in Q3 2022, an estimated $351K.
  • Kohlberg Kravis Roberts & Co first reported a position in Calidi Biotherapeutics in Q4 2021 and held it in 3 quarters.
  • Kohlberg Kravis Roberts & Co's Calidi Biotherapeutics position peaked at $351K in Q2 2022.
  • 21 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q3 2022.

Based on Kohlberg Kravis Roberts & Co's 13F filing for Q3 2022, filed 14 Nov 2022.